



EUROPEAN
HEMATOLOGY
ASSOCIATION

 **haematologica**

Journal of the European Hematology Association
Owned & published by the Ferrata Storti Foundation

AUTHOR CONTRIBUTION FORM

Title	Multi-center randomized open label phase II trial on 3 rituximab dosing schemes in immune thrombocytopenia patients.
First author	Jaap Jan Zwaginga

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author (<i>author responsible for the integrity of the work as a whole</i>)
Name: prof. dr. J.J. Zwaginga
Institute: Leiden University Medical Center, Dept of Immunohematology and Blood transfusion, Leiden, the Netherlands
e-mail: j.j.zwaginga@lumc.nl

Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :

J.J. Zwaginga, created and designed the study, analyzed data, writing the manuscript
B. van der Holt, analysed data, assisted writing the manuscript
P.A. te Boekhorst, included patients, critically revising the final manuscript
B.J. Biemond, designed the study, included patients,
M-D. Levin, included patients, critically revising the final manuscript
R. van der Griend, included patients, critically revising the final manuscript
A. Brand, included patients, critically revising the final manuscript
S. Zweegman, included patients, critically revising the final manuscript
J.F.M. Pruijt, included patients, critically revising the final manuscript
V.M.J. Novotny, included patients, critically revising the final manuscript
A.Vreugdenhil, designed the study, included patients and critically revising the final manuscript

M.R. de Groot, included patients
O. de Weerd, included patients
E.C.M. van Pampus, included patients and critically revising the final manuscript
T.M. van Maanen-Lamme, included patients
S. Wittebol, included patients,
M.R. Schipperus, included patients, critically revising the final manuscript
M.H. Silbermann, included patients
P.C. Huijgens, designed the study, critically revising the final manuscript
M. Luten, collected the clinical data, critically revising the final manuscript
R. Hollestein, collected the clinical data, critically revising the final manuscript
J.A.C. Brakenhoff, included patients
J.G. Schrama, included patients
F.A.A. Valster, included patients
G.A. Velders, included patients
H.R. Koene, created and designed the study, included patients, analyzed data, assisted writing the manuscript
All authors approve on publishing the manuscript in Haematologica